The company has also appointed James Hardy as an investor and strategic advisor.
"What really stood out to me was the strength of the team and the clarity of the model. incentifi is built around improving healthier lives while delivering a clear return for employers and partners. Having seen first-hand at Bioniq how impactful it can be when wellbeing and business objectives truly align, incentifi delivers exactly that. I’m excited to be part of the journey ahead."
The London-based NatureTech startup secured $4m to scale its platform and deploy new artificial intelligence tools for nature recovery.
"As threats to the natural world become more urgent, any organisation dependent on land – whether directly or through their supply chain – has a business resilience need to invest in nature recovery."
The financing extension brings Nuclera's total Series C funding to $87m and will advance antibody engineering capabilities.
"Since our initial investment, Nuclera has made meaningful progress in expanding the capabilities, adoption, and global reach of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a significant step forward, particularly as biologics discovery becomes increasingly driven by AI-enabled workflows that require scalable, high-quality datasets. Elevage is proud to continue supporting Nuclera as it evolves into a foundational platform for protein and antibody engineering, helping researchers accelerate discovery timelines and reduce friction across the drug development process."
BGF has backed the water technology provider with new funding to accelerate product development and overseas expansion.
"In 2019, we set out on a mission to become water industry innovators by blending technology and engineering to drive down water loss and protect the environment."